COMPARISON

Ciclosporin vs Triptorelin

5 attributes held for at least one of the two. 4 differ. Each value carries the register it came from and the date that register was read.

Answer

Ciclosporin is authorised or registered in 9 and Triptorelin in 10 of the 10 registers read. Ciclosporin: highest phase Phase 4 (after approval). Triptorelin: highest phase Phase 4 (after approval). 0 registered trials include both.

States no view on which is preferable, safer or more effective. Not medical advice.

CiclosporinTriptorelin
Registered trials
differs
1328
clinicaltrials.gov · 2026-10-03
317
clinicaltrials.gov · 2026-10-03
FDA label
differs
FDA label, application not recorded: VEVYE
openfda · 2026-08-31T07:37:14Z
FDA-approved: Trelstar
openfda · 2026-10-03T17:23:44.062Z
EU authorisation
Authorised
ema · 2026-10-03
Authorised
ema · 2026-08-31
EU authorised on
differs
2015-03-19
ema · 2026-10-03
Not checked
no record of "authorisedOn" for triptorelin
ATC code
differs
S01XA18
ema · 2026-10-03
Not checked
no record of "atcCode" for triptorelin

SIDE EFFECTS

Most common side effects, each beside its own placebo

Side effectCiclosporinplaceboTriptorelinplacebo
Punctate Keratitis5.8%4.5%--

Trial register Ciclosporin: 7 placebo-controlled trials; Triptorelin: 0. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Ciclosporin side effects · Triptorelin side effects

LEGAL STATUS

Approval in each country read

CountryCiclosporinTriptorelinRegister
United StatesFDA label, application not recordedFDA-approvedRegulator FDA
European UnionAuthorisedAuthorisedRegulator EMA
United KingdomAuthorisedAuthorisedRegulator MHRA
CanadaAuthorisedAuthorisedRegulator Health Canada
AustraliaRegisteredRegisteredRegulator TGA
SwitzerlandAuthorisedAuthorisedRegulator Swissmedic
BrazilRegistadoRegistadoRegulator ANVISA
SerbiaAuthorisedAuthorisedRegulator ALIMS
SingaporeRegisteredRegisteredRegulator HSA
TurkeyRuhsatliRuhsatliRegulator TITCK

Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.

WEEKLY

Register Watch, weekly

New trials, approvals and enforcement actions. One email a week.